Chemical manufacturing giant Bayer announced Tuesday it will offer $7.25 billion in a class action settlement aimed at resolving thousands of legal cases alleging the company’s popular herbicide Roundup is linked to cancer.
The pharmaceutical and agriculture company’s head of litigation, Bill Dodero, discussed the proposed agreement during a Tuesday conference call with investors and media representatives. Dodero explained that the settlement would resolve multiple outstanding legal issues.
“By that, we mean addressing all of the present and potential claims of non-Hodgkins Lymphoma,” Dodero stated during the call.
The proposed settlement represents Bayer’s latest attempt to put an end to the mounting legal challenges surrounding Roundup, one of the world’s most widely used weed-killing products. The company has faced numerous lawsuits from plaintiffs who claim exposure to the glyphosate-based herbicide led to their cancer diagnoses.
